Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2016)
16 slides from Genetic Technologies's shareholder meeting presentation, Nov 23, 2016
Slide 1: ASX Announcement: 2016 Annual General Meeting
For personal use only ASX ANNOUNCEMENT 23 November 2016 2016 Annual General Meeting Melbourne, Australia; 23 November 2016: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) is pleased to release the attached slide show presentation which will be delivered by its Chief Executive Offic
Slide 2: Genetic Technologies Limited Annual General Meeting
Genetic Technologies Limited For personal use only Annual General Meeting Wednesday, 23 November 2016 1
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business ach
Slide 4: Major Achievements Since Last AGM
Major Achievements Since Last AGM For personal use only 2015 was transformative on the back of the $18.6m capital raise in March 2015 Raising the profile of BREVAGenplus® with the consumer and medical communities was our top priority in 2016 Partnered with Verizon IndyCar® series driver Pippa Mann t
Slide 5: Major Achievements Since Last AGM (Cont.)
Major Achievements Since Last AGM (Cont.) For personal use only Growth strategy successfully supported with - The publication of two new papers demonstrating BREVAGenplus’ clinical validation, further adding to already existing scientific evidence base for BREVAGenplus - The addition of key members
Slide 6: Brand Awareness-Exclusive Spokesperson
Brand Awareness-Exclusive Spokesperson For personal use only Verizon IndyCar series driver Pippa Mann has become the exclusive spokesperson for BREVAGenplus. BREVAGenplus.com, supportive marketing collateral and social media are aligned with the Pippa Mann image and the "Know Your Risk" call to acti
Slide 7: Nasdaq MarketSite Video - Times Square, NYC
Nasdaq MarketSite Video - Times Square, NYC For personal use only 6
Slide 8: First Quarter - FY17 Update
First Quarter - FY17 Update For personal use only …With a stable and growing customer base, we entered 2017 with momentum First quarter Test samples received was 23% higher than that achieved in the previous quarter (Q4 FY16) Average revenue per test receipt in the first quarter was 11% higher than
Slide 9: What is BREVAGenplus?
What is BREVAGenplus? For personal use only Simple cheek swab based test that helps determine a woman’s risk of developing sporadic breast cancer Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation among people. The SNPs used in BREVAGenplus have been confirmed to be
Slide 10: USPSTF Recommendation Statement
USPSTF Recommendation Statement For personal use only United States Preventative Services Task Force (USPSTF) Population Recommendation Grade Women, Increased Risk The USPSTF recommends that B – This B grade rating clinicians engage in shared, signifies the level of evidence for Breast Cancer inform
Slide 11: Importance of USPSTF Recommendation
Importance of USPSTF Recommendation For personal use only The effective application of the USPSTF recommendation, by physicians, would mean that ALL women should be offered a risk assessment… BRCA/Panel testing Receive USPSTF Annual Patient visit to screen for germline ObGyn mutation testing BREVAGe
Slide 12: BREVAGenplus' Value Proposition
BREVAGenplus’ Value Proposition For personal use only United States Preventive Services Task Force (USPSTF) (April 2013) recommends the use of Tamoxifen/Raloxifene in high risk women - BREVAGenplus can provide the information required to guide Tamoxifen use The Affordable Care Act stipulates that: –
Slide 13: Key Market Drivers
Key Market Drivers For personal use only Scientific validation and clinical utility studies − R&D to deliver further validation data, to include commercial R&D collaboration with several risk assessment clinics in the U.S. − Positive outcomes from clinical utility studies will drive further growth,
Slide 14: Market Progress
Market Progress For personal use only BREVAGenplus is available in all 50 U.S. states, including NY State – Samples received from high population density territories – 9,742 Test Samples received to June 2016, since launch of BREVAGen, in June 2011. BREVAGenplus released in October 2014 Established
Slide 15: Priorities for FY2017
Priorities for FY2017 For personal use only Complete two of the three, in progress, scientific validation studies demonstrating the “clinical utility” of the test Enhance the validation base of BREVAGenplus in terms of ethnicity and age Strengthen medical affairs presence to enhance relationships wi
Slide 16: BREVAGenplus Spokesperson Pippa Mann
BREVAGenplus Spokesperson Pippa Mann For personal use only As featured in the in the official Indy 500 Program and the USA Today special commemorative edition, about the race 15
Genetic Technologies — Shareholder Meeting (November 2016) on 6ix